Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccines 64

Vaccines Health and Personal Care Stores Immunization Communication 64

Pharmaceutical Technology

MAY 4, 2023

After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).

Vaccines 64

Vaccines FDA Communication Immunization 64

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 64

pharmaphorum

MARCH 23, 2021

In the fight against emerging coronavirus variants and spike mutations, the need for long-lasting immunity is greater than ever. This is why the time is now to look beyond antibodies and capitalize on the long-term immune response of T cell therapies. Download the event guide here. Gavin MacBeath, CSO, TScan Therapeutics.

Immunization 52

Immunization Vaccines 52

Pharmaceutical Technology

MAY 1, 2023

After a long period of inactivity in RSV vaccine development , two pharmaceutical companies are now approaching regulatory decisions for their RSV vaccines. Both Pfizer and GSK have major approval decisions regarding the use of their RSV vaccines for older adults this May. What incentivises a country to cover a vaccine?

Vaccines 52

Vaccines Nursing Homes Pharmaceutical Companies Pharmaceutical Companies 52

Digital Pharmacist

OCTOBER 25, 2023

You can even download additional resources and graphics related to national diabetes day at this link. Promote Routine Immunizations People with diabetes are at a higher risk of complications from infections.

Immunization 105

Immunization Vaccines 105

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

European Pharmaceutical Review

JUNE 28, 2024

The post <em>European Pharmaceutical Review </em> Issue 3 2024 appeared first on European Pharmaceutical Review.

Research Laboratories 52

Research Laboratories Vaccines Immunization 52

Pharmaceutical Technology

DECEMBER 1, 2022

A clinical-stage biopharmaceutical firm, Liminatus focuses on the development of new therapies for cancer that utilises the immune system of the body to detect and fight cancer cells. The GCC Vaccine is being analysed in Phase II clinical trials. The boards of directors of both companies have granted approval for the merger.

Immunization 52

Immunization Vaccines Communication 52

pharmaphorum

AUGUST 16, 2022

Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. . Download the full event guide to find out more.

Immunization 52

Immunization Vaccines 52

Pharmaceutical Technology

MAY 24, 2023

Morphogenesis’s technologies include Immune Fx (IFx) personalised cancer vaccines and tumour microenvironment (TME) modulators. IFx has been designed to activate an innate immune response against tumour antigens that are patient-specific. Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0,

Vaccines 52

Vaccines Immunization 52

Pharmaceutical Technology

JUNE 8, 2023

The partnership’s initial focus is to support drug developers to advance cell and gene therapies (CGT) using pioneering modalities including viral vectors (AAV, LVV, RV and HSV), antibodies (mAb, bsAb and ADC), CAR-T therapies and vaccines (DNA, mRNA and protein).

Vaccines 52

Vaccines Immunization Hospitals 52

Pharmaceutical Technology

MARCH 21, 2023

Source: GlobalData Pharmaceutical Intelligence Center Clinical trial catalysts In late January, AC Immune released positive interim results from the Phase I/II trial (NCT05462106) studying the company’s vaccine in patients with prodromal Alzheimer’s disease. Please check your email to download the Report.

Packaging 59

Packaging FDA Vaccines Communication 59

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 20, 2023

The capabilities of Viroclinics and DDL allowed us to rapidly test repurposed drugs, new vaccines and antiviral solutions for the prevention and treatment of patients affected by COVID-19 in 2020. Please check your email to download the Whitepaper. What future developments are you most excited about being part of Cerba Research?

Vaccines 52

Vaccines Communication Immunization 52

Pharmacy Friday Pearls

MARCH 4, 2022

Download PDF. 1 risk factor for progression to severe disease a No prior COVID-19 vaccine or infectionStandard of care treatment allowed but primary analysis population was limited to subjects who did NOT receive COVID-19 monoclonal antibodies COVID-19 related hospitalizations/death through day 28: 0.8% Author: Alyssa Lear, PharmD.

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Hospitals Packaging Immunization 40

Pharmaceutical Technology

FEBRUARY 24, 2023

On December 20, 2022, the World Health Organization (WHO) updated its recommendations for cervical cancer vaccines in a bid to boost vaccination coverage. Several cervical cancer vaccines are currently approved, including Merck’s nonavalent vaccine Gardasil 9 and GSK’s bivalent vaccine Cervarix.

Vaccines 116

Vaccines Communication Medical Schools Immunization 116